| Market Cap | 9.37B 8.22B 7.58B 7.09B 13.3B 884B 13.58B 91.06B 35.23B 437B 35.2B 34.43B 1,515B | P/E 2026 * |
167x | P/E 2027 * | 36.2x |
|---|---|---|---|---|---|
| Enterprise Value | 9.16B 8.03B 7.4B 6.93B 13B 864B 13.27B 88.99B 34.43B 427B 34.4B 33.65B 1,481B | EV / Sales 2026 * |
9.11x | EV / Sales 2027 * | 6.36x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 31/12/1998 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 28/02/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 31/12/1998 |
James Wilson
CHM | Chairman | 82 | 31/12/1998 |
David Mahoney
BRD | Director/Board Member | 71 | 30/06/2004 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 9.37B | |
| +7.13% | +9.97% | +55.80% | +163.38% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +56.27% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.19% | 448B | |
| +0.49% | +4.85% | +28.17% | +22.04% | 332B | |
| -0.32% | +7.37% | +41.01% | +27.00% | 293B | |
| -0.33% | +4.51% | +30.71% | +41.03% | 286B | |
| -1.03% | +4.83% | -28.47% | -41.05% | 215B | |
| +1.56% | +6.14% | +29.30% | +61.91% | 193B | |
| +3.26% | +3.33% | +15.55% | +67.87% | 159B | |
| Average | -0.24% | +8.48% | +30.90% | +54.41% | 401.79B | |
| Weighted average by Cap. | +0.20% | +9.65% | +41.72% | +80.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.01B 882M 813M 761M 1.43B 94.91B 1.46B 9.77B 3.78B 46.9B 3.78B 3.7B 163B | 1.4B 1.23B 1.13B 1.06B 1.99B 132B 2.03B 13.6B 5.26B 65.28B 5.26B 5.14B 226B |
| Net income | 85.73M 75.17M 69.29M 64.87M 122M 8.09B 124M 833M 322M 4B 322M 315M 13.86B | 369M 323M 298M 279M 523M 34.77B 534M 3.58B 1.39B 17.18B 1.38B 1.35B 59.58B |
| Net Debt | -213M -187M -172M -161M -303M -20.13B -309M -2.07B -802M -9.95B -801M -784M -34.5B | -474M -416M -383M -359M -673M -44.73B -687M -4.61B -1.78B -22.11B -1.78B -1.74B -76.66B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
